Facebook Pixel Code
CF banner image

Research Resources

We have also developed many CF research resources which are employed both locally and globally to understand the disease and develop therapies:

The Mutation Database

The CF genetic defect was discovered at The Hospital for Sick Children in 1989 in the laboratories of John Riordan and Lap-Chee Tsui. Subsequently, Dr. Tsui established the Cystic Fibrosis Genetic Analysis Consortium (CFGAC) to enable CF researchers and clinicians to pool information on new mutations as soon as they were identified. This information led to the creation of the Cystic Fibrosis Mutation Database (CFMD). The CF mutation database is an internationally renowned reference for CFTR mutations and continuously used and contributed to by researchers throughout the world. A high percentage of CF articles published since 1989 have a reference linking to the database.

Management Structure

Scientific Director

Johanna Rommens PhD
Genetics and Genomic Biology
The Hospital for Sick Children


Ruslan Dorfman PhD
Genetics and Genomic Biology
The Hospital for Sick Children

Staff Programmer

Edgar Crowdy
Centre for Computational Biology
The Hospital for Sick Children

Advisory Committee

Christine Bear PhD
Molecular Medicine
The Hospital for Sick Children

Mary Corey PhD
Child Health Evaluative Sciences
The Hospital for Sick Children

Peter Durie MD
Gastroenterology, Hepatology and Nutrition
The Hospital for Sick Children

Felix Ratjen MD
Respiratory Medicine
The Hospital for Sick Children

Peter Ray PhD
Molecular Genetics
The Hospital for Sick Children

Lisa Strug PhD
Genetics & Genome Biology
The Hospital for Sick Children

Founder, External Advisor

Lap-Chee Tsui
Vice Chancellor and President
The University of Hong Kong

The Patient/Biostatistics

The Toronto CF database provides an overall structure for maintaining and connecting all the available patient data in both Toronto CF clinics at SickKids and the St. Michael’s Hospital Adult CF Centre. The combined database facilitates longitudinal studies relating lifetime outcomes to mutations in the CFTR gene. Core support from this data base ensures that scientists have access to the most appropriate patient information and material to design experiments and clinical trials.

The CF Mouse Core

Provides the infrastructure to supply the mice which model CF disease and are required to study disease mechanisms as well as pre-clinical trials of therapeutic agents. This core is vital to the success of our mandate to assess the efficacy of novel CF therapies.

High through-put Screening Core

CFI funded a high through-put proteomic screens (called the SIDNET initiative). Currently, this infrastructure is being used for high through-put screens of proteins and cellular pathways which impact on mutant CFTR biosynthesis, trafficking and function as well as screens of chemical libraries of potential drugs for CF treatment. SIDNET is part of a larger infrastructure platform called SPARC Biocentre

CF Seminar Series

This series of lectures provides a valuable educational tool and promotes effective communication between scientists, clinicians and allied personnel through seminars and cross-disciplinary collaborations for the past two decades. The series runs weekly and offers a forum for established scientists and clinicians, as well as junior trainees to showcase their work and research.